The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain. Journavx received FDA ...

Perspective from Anita Gupta, DO, PharmD, MPP, GMP, FASA The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a press release.

The prognosis for mild TBI is usually better than for a moderate TBI, and the prognosis for moderate TBI is usually better than for a severe TBI. With a concussion (mild TBI), most people recover most ...